Predicting Response to Anthracyclines in Ovarian Cancer

Annamaria Ferrero, Martina Borghese, Stefano Restaino, Andrea Puppo, Giuseppe Vizzielli and Nicoletta Biglia
Additional contact information
Annamaria Ferrero: Academic Department of Gynaecology and Obstetrics, Mauriziano Hospital, 10128 Torino, Italy
Martina Borghese: Department of Gynecology and Obstetrics, Santa Croce and Carle Hospital, 12100 Cuneo, Italy
Stefano Restaino: Obstetrics and Gynecology Unit, Department of Obstetrics, Gynecology and Pediatrics, Department of Medical Area DAME, Udine University Hospital, 33100 Udine, Italy
Andrea Puppo: Department of Gynecology and Obstetrics, Santa Croce and Carle Hospital, 12100 Cuneo, Italy
Giuseppe Vizzielli: Clinic of Obstetrics and Gynaecology, Department of Medical Area (DAME), University of Udine, “Santa Maria della Misericordia” Hospital, Azienda Sanitaria Ospedaliera Friuli Centrale, 33100 Udine, Italy
Nicoletta Biglia: Academic Department of Gynaecology and Obstetrics, Mauriziano Hospital, 10128 Torino, Italy

IJERPH, 2022, vol. 19, issue 7, 1-15

Abstract: (1) Background: Anthracyclines are intriguing drugs, representing one of the cornerstones of both first and subsequent-lines of chemotherapy in ovarian cancer (OC). Their efficacy and mechanisms of action are related to the hot topics of OC clinical research, such as BRCA status and immunotherapy. Prediction of response to anthracyclines is challenging and no markers can predict certain therapeutic success. The current narrative review provides a summary of the clinical and biological mechanisms involved in the response to anthracyclines. (2) Methods: A MEDLINE search of the literature was performed, focusing on papers published in the last two decades. (3) Results and Conclusions: BRCA mutated tumors seem to show a higher response to anthracyclines compared to sporadic tumors and the severity of hand–foot syndrome and mucositis may be a predictive marker of PLD efficacy. CA125 can be a misleading marker of clinical response during treatment with anthracyclines, the response of which also appears to depend on OC histology. Immunochemistry, in particular HER-2 expression, could be of some help in predicting the response to such drugs, and high levels of mutated p53 appear after exposure to anthracyclines and impair their antitumor effect. Finally, organoids from OC are promising for drug testing and prediction of response to chemotherapy.

Keywords: anthracyclines; pegylated liposomal doxorubicin; BRCA mutation; chemotherapy; immunohistochemistry; immunotherapy; organoids; ovarian cancer; p53; response rate (search for similar items in EconPapers)
JEL-codes: I I1 I3 Q Q5 (search for similar items in EconPapers)
Date: 2022
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.mdpi.com/1660-4601/19/7/4260/pdf (application/pdf)
https://www.mdpi.com/1660-4601/19/7/4260/ (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:gam:jijerp:v:19:y:2022:i:7:p:4260-:d:785937

Access Statistics for this article

IJERPH is currently edited by Ms. Jenna Liu

More articles in IJERPH from MDPI
Bibliographic data for series maintained by MDPI Indexing Manager ().